MediFind

Find a Doctor

Tilmann Bochtler

University Of Heidelberg

Bio


Tilmann Bochtler is in Heidelberg, Germany. They have been an author on 51 peer reviewed articles and participated in 2 clinical trials in the past 15 years. Dr. Bochtler's top three areas of expertise are Primary Amyloidosis, Acute Myeloblastic Leukemia with Maturation, and Acute Myeloblastic Leukemia without Maturation.

Contact

Heidelberg, BW, DE

Latest Research


Latest Advance
Study
  • Condition: Hematological Relapse in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)
  • Journal: The Lancet. Oncology
  • Treatment Used: Measurable Residual Disease-Guided (MRD-Guided) Treatment with Azacitidine (RELAZA2)
  • Number of Patients: 198
  • Published —
This study evaluated the effectiveness of measurable residual disease-guided (MRD-guided) preventive treatment with azacitidine (RELAZA2) in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who achieve a morphological complete remission and they can predict to have a hematological relapse.

All Publications
View All


Publication
Study
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Published —
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.

Contact

Heidelberg, BW, DE

Insurance

Contact them to find out if they accept your insurance plan.